Add code preparation CD47 single anti-Xinda biological domestic once again submitted a new application for clinical trials

Author . . On September 12, CDE's official website showed that Xinda Bio had submitted a clinical trial application for IBI188 in China and had been accepted by CDE, which is the fourth clinical trial application for IBI188 in China.
data source: CDE recombinant all-human anti-CD47 monoclonal antibody IBI188 Cyntaf biodeveloped recombinant all-human source anti-CD47 monoclonal antibody IBI188 is an IgG4 monoclonal antibody, can bind to CD47 antigen specificity on the surface of tumor cells, block CD4 The 7-SIRP alpha signaling path, which inhibits the "don't eat me" signal transmitted by CD47, causes macrophages to recognize the "eat me" signal transmitted by tumor cells, thereby devouring tumor cells and exerting the body's anti-tumor effects, and is intended to be used to treat a variety of blood tumors and solid tumors, including non-Hodgkin's lymphoma and ovarian cancer.
it is worth mentioning that, in addition to IBI188 single resistance, Ida Bio's in-study product pipeline also has a new dual-specific antibody that can target both CD47 and PD-L1.
this double anti-resistant product was approved in China in January 2020 for clinical use in the treatment of physical tumors and blood tumors and other adaptive disorders.
, China and the United States synchronized clinical in early September 2018, Xinda BioCD47 monoantibas in the study product IBI188 was issued by the State Drug Administration of China clinical trial approval.
, IBI188 received FDA-issued approval for clinical trials of drugs intended for the treatment of advanced malignancies and lymphomas.
Up to now, Xinda Bio has launched 3 clinical trials in China around IBI188 monoantitones, and the adaptations include high-risk bone marrow hyperplising abnormal syndrome, acute myeloid leukemia, and advanced malignant tumors in the initial diagnosis, and IBI188 has entered the stage of simultaneous clinical trials between China and the United States.
source: Drug clinical trial registration and information publicity platform has been approved clinical similar products as one of the hot targets in the field of anti-tumor immunotherapy, CD47 has been the industry as PD-1/PD-L1 antibodies, the next "star" in the field of tumor immunity, has become a hot spot in domestic and foreign research.
, no CD47 antibodies have been approved for market worldwide.
, according to incomplete statistics, more than 20 companies are currently involved in the development of CD47 target antibodies worldwide, including Forty Seven, which is developing CD47 antibodies.
in early March, Gilead Sciences bought Forty Seven for $4.9 billion, sparking renewed industry interest in CD47 antibody immunotherapy.
of the pharmaceutical companies preparing CD47 antibodies in China, 7 CD47 antibodies from five pharmaceutical companies have been approved for clinical trials, including 4 single antibodies and 3 CD47 dual specific antibodies.
data source: public data collated from the current clinical trial situation, Xinda Bio in the cd47 single-resistance product IBI188 development progress is fast.
is also noteworthy that, in addition to Ida Bio's IBI188, Tianbi's CD47 monoantibasing product TJC4 was launched in the United States in June 2019.